Skip to content


Tracleer (bosentan) is a small molecule pharmaceutical. Bosentan was first approved as Tracleer on 2001-11-20. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension and systemic scleroderma. The pharmaceutical is active against endothelin receptor type B. In addition, it is known to target endothelin-1 receptor. Tracleer's patent is valid until 2027-12-28 (FDA).
Trade Name Tracleer
Common Name Bosentan
Indication pulmonary hypertension, systemic scleroderma
Drug Class Endothelin receptor antagonists
Get full access now